Compared to non-small cell lung carcinoma (NSCLC), PARP1 protein level was higher in small cell lung cancer (SCLC), leading to higher sensitivity of SCLC to PARP1 inhibitors [29]. The gene discussed is PARP1; the disease is small cell lung carcinoma.